There are currently 974 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321
Recruiting
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Next Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor, NSCLC
Register for Updates
Neural Connectivity During Therapy for Adolescent PTSD
NCT05423444
Recruiting
Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/30/2024
Locations: UT Health Department of Psychiatry, San Antonio, Texas
Conditions: PTSD, Adolescent, Psychological Trauma
Register for Updates
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06507306
Recruiting
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Solid Tumor, Adult
Register for Updates
Genomic Predictors of Recurrent Pregnancy Loss
NCT05444283
Recruiting
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/19/2024
Locations: University of Texas at San Antonio, San Antonio, Texas
Conditions: Recurrent Pregnancy Loss
Register for Updates
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135
Recruiting
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Texas Mays Cancer Center, San Antonio, Texas
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Texas Mays Cancer Center, San Antonio, Texas
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
NCT05827614
Recruiting
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Non-small Cell Lung Cancer, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Liposarcoma
Register for Updates
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782
Recruiting
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor
Register for Updates
National Adaptive Trial for PTSD Related Insomnia
NCT03668041
Recruiting
Many Veterans with posttraumatic stress disorder (PTSD) have trouble sleeping or have frequent nightmares. So far, no medication has been approved for treatment of insomnia in PTSD. The purpose of this research study is to find out if taking medications called trazodone or eszopiclone can help decrease symptoms of insomnia in patients with PTSD. PTSD is a form of intense anxiety which sometimes results from severe trauma. Symptoms may include nightmares, flashbacks, troublesome memories, difficu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/18/2024
Locations: South Texas Health Care System, San Antonio, TX, San Antonio, Texas
Conditions: Insomnia
Register for Updates
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
NCT06609343
Recruiting
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysi... Read More
Gender:
ALL
Ages:
Between 25 years and 74 years
Trial Updated:
12/17/2024
Locations: University Hospital Dialysis Medical Center (DMC), San Antonio, Texas
Conditions: End Stage Renal Disease, Fatigue
Register for Updates
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
NCT04789044
Recruiting
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/17/2024
Locations: San Antonio Military Medical Center (SAMMC), San Antonio, Texas
Conditions: Peripheral Nerve Injuries
Register for Updates